CD276 and neoplasm: We first established B7-H3 as a targetable antigen for CAR T therapy against GBM based on (1) its tumor-specific high expression in GBM cell lines and patient samples (Fig. 1), and (2) its ability in engaging and activating B7-H3 targeting CAR T cells for tumor clearance (Fig. 2).